US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 04:26:39 Source:opinionsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
You may also like
- Joe Rogan's 'brain
- Revealed: Shocking extent of anti
- Australian gov't confirms 2nd consecutive budget surplus
- VP Harris was gifted tickets to Beyoncé's show by the artist herself
- Harris accepts debate invite to face off with Trump's VP pick, which may come at convention
- Caitlin Clark's WNBA debut helps ESPN set viewership record for league game on network
- Moment disqualified hit
- Who is Robert Fico? Slovakia Prime Minister shot multiple times
- What's next for Iran after death of its president in crash?